▲ Peaking
Business
A biotech hedge fund births a new immunology company
A biotech hedge fund’s spin‑out sparks a 467% stock surge as a modest $16.5 million reverse merger launches North Immunology.
Atopic Dermatitis
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Atopic Dermatitis
This hub groups 3 separate news trends connected to Atopic Dermatitis, spanning July 24, 2026 through September 17, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 17 article observations and 17 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Regeneron backs $75M series A for antibody upstart Infinimmune
Alameda-based biotech Infinimmune has secured $75 million in Series A funding to advance its antibody pipeline for atopic dermatitis and inflammatory diseases.
◼ Archived
Business
🔮 fades ✓
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi's decision to abandon an eczema drug from its $1.1B Kymab acquisition raises questions about its pipeline strategy.